SPOTLIGHT -
New Platform "Simplifies and Optimizes Development of Adherence Programs"
Reducing Barriers to Great Patient Care and Supporting Product Success
As manufacturers look to commercialize new medicines, it is important to evaluate partners that can provide a fully integrated offering aligned to product performance goals and offer a seamless customer experience.
Report Surveys Unmet Needs and Attitudes of People Living with RA
The Future of Cell and Gene Therapy
Each year, the success of cell and gene therapy becomes clearer, but what do we really know about it?
Sharing Your Voice
The lifeblood of our coverage are the many interviews we conduct with industry executives-and the unique stories and insights they provide. Here, I highlight excerpts from a selection of wide-ranging conversations from the past year.
Merck's Keytruda approved in China
Operations: Gateway to Success in Cell and Gene Therapies
Life sciences therapies are moving away from a one-size-fits-all approach to a targeted approach using a patient's own genetic information and immune system to treat previously incurable diseases.
Pharmaceutical Executive, April 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2019 issue in an interactive PDF format.
Country Report: China
Declaring it a “strategic sector for priority development,” China has opened up the floodgates for sweeping reforms of the nation’s healthcare infrastructure-a watershed moment for the Chinese pharmaceutical and healthcare industries, where all stakeholders will have to adapt to the new rules of the game.
Daelight Solutions and Docxonomy Partner for Veeva Vault Clients
Clarivate Analytics Drugs to Watch Report
Pharmascience Implements OpenText Document Management
RAPS Statement - BREXIT delay
Regulatory Affairs Professionals Society's Executive Director, Paul Brooks, discusses the looming uncertainty about what will happen after the UK leaves the European Union as many important details remain unclear.
Deloitte Launches 10th Annual Accounting and Financial Report
Universal Medica Group and EVERSANA Partner
KOLs: An Endangered Buzzword
KOLs have traditionally exerted their influence through research and publication on drug safety and efficacy, but now share the stage with other important measures.
EVERSANA Unveils Global Market Access Research Solution
Patient Input and Patient Preference Studies
Patient preferences are increasingly seen as valuable in healthcare policy decision-making, but such studies are not always easy to design and implement, writes Nick Hicks.
Is There Evidence in Real-World Evidence?
The discrepancies between trial and real-life patient conditions are such that Real-World Evidence (RWE) can be utilized to supplement this process.
FDA Only Winner as New Budget Battle Begins
The FDA planned budget features added funds allotted to improved oversight of drugs, biologics, and medical devices.
FDA Modernizes Controlled Correspondence Interactions with Pharma Industry
As part of FDA’s ongoing effort to modernize interactions with industry, FDA launched a portal to help with submissions of controlled correspondence via email instead of manual data entry.
PAREXEL's Inaugural Podcast Focuses on International Women's Day
Pharm Exec Joins MJH Portfolio
Michael J. Hennessy Jr., president of MJH Associates‚ Inc., answers questions about the acquisition of UBM Life Sciences media brands and his company’s perspective on the evolving biopharma landscape.
Gottlieb is Stepping Down From the FDA’s Most Forward-Looking Chapter
We’re about to lose the most tech-savvy FDA chief in recent memory, writes Pratap Khedkar.
Accenture to Acquire Ireland's Enterprise System Partners
Brenda Snow: Advancing the Patient Story
Brenda Snow talks to Pharm Exec about the creation of Snow Companies, the first full-service agency to bring strategic, regulatory-compliant, real-life patient stories to direct-to-patient initiatives.
Pharmaceutical Executive, March 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2019 issue in an interactive PDF format.
Country Report: France
After a prolonged period of relative stagnation, the strategically influential, clinically rich French life sciences market suddenly seems to be rediscovering its mojo-thrusting the pharma and medtech sectors into the spotlight.
CPhI Set for Thailand Amid 'Booming' South East Asia Pharma Market
MassBio Releases Digital Health Study for Massachusetts